贝伐珠单抗联合XELOX方案对晚期结肠癌患者肿瘤标志物水平及免疫功能的影响  

Effect of Bevacizumab Combined with XELOX Regimen on Tumor Marker Levels and Immune Function in Patients with Advanced Colon Cancer

作　　者：刘玲[1] 戴新龙 陈许宇 王思颖 李娟[1] LIU Ling;DAI Xinlong;CHEN Xuyu;WANG Siying;LI Juan(Department of Oncology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing 210000,China;Department of General Surgery,Sihong County First People's Hospital,Sihong 223900,China;Department of Gastroenterology,The Affiliated Hospital of Yangzhou University,Xuzhou 225000,China)

机构地区：[1]南京医科大学第二附属医院肿瘤科,江苏南京210000 [2]泗洪县第一人民医院普外科,江苏泗洪223900 [3]扬州大学附属医院消化内科,江苏扬州225000

出　　处：《反射疗法与康复医学》2024年第24期128-131,共4页Reflexology And Rehabilitation Medicine

摘　　要：目的探讨晚期结肠癌患者采用贝伐珠单抗(BEV)联合奥沙利铂、卡培他滨(XELOX)方案治疗的临床效果。方法选取2021年6月—2024年1月南京医科大学第二附属医院收治的100例晚期结肠癌患者为研究对象,按随机数字表法将其分为对照组和观察组,每组50例。对照组采用XELOX方案治疗,观察组在对照组的基础上采用BEV治疗,两组患者均持续治疗4个周期。对比两组的临床疗效、肿瘤标志物、免疫功能、不良反应发生情况。结果观察组客观缓解率、疾病控制率分别为64.00%、82.00%,均高于对照组的40.00%、62.00%,组间差异有统计学意义(P<0.05)。治疗后,观察组糖类抗原199(CA199)、癌胚抗原(CEA)水平均低于对照组,组间差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)水平、CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,组间差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论晚期结肠癌患者采用BEV与XELOX方案联合治疗可降低CA199及CEA水平,改善免疫功能,增强抗肿瘤效果,且安全性好。Objective To explore the clinical effect of treating patients with advanced colon cancer using the combination of bevacizumab(BEV)and the oxaliplatin-capecitabine(XELOX)regimen.Methods One hundred patients with advanced colon cancer admitted to The Second Affiliated Hospital of Nanjing Medical University from June 2021 to January 2024 were selected as the research subjects.They were divided into a control group and an observation group according to the random number table method,with 50 patients in each group.The control group was treated with the XELOX regimen,and the observation group was treated with BEV on the basis of the control group,both groups of patients were continuously treated for 4 cycles.The clinical efficacy,tumor markers,immune function,and occurrence of adverse reactions of the two groups were compared.Results The objective response rate and disease control rate in the observation group were 64.00%and 82.00%,respectively,which were higher than 40.00%and 62.00%in the control group,and the differences between the two groups were statistically significant(P<0.05).After treatment,the levels of carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)in the observation group were lower than those in the control group,and the differences between the two groups were statistically significant(P<0.05);the levels of CD3^(+),CD4^(+)and the ratio of CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,while the level of CD8^(+)was lower than that in the control group,and the differences between the two groups were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Combined treatment with BEV and the XELOX regimen in patients with advanced colon cancer can reduce the levels of CA199 and CEA,improve immune function,enhance the anti-tumor effect,and it has good satety.

关 键 词：晚期结肠癌 贝伐珠单抗 化疗 肿瘤标志物 免疫功能 

分 类 号：R735.3[医药卫生—肿瘤]